This study compares Nadofaragene Firadenovec, a treatment, with just watching (observation) in people with a certain kind of bladder cancer called Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC). Bladder cancer happens when cells in the bladder grow abnormally. The study is for people who have had surgery to remove their bladder tumor within 60 days before joining the study.

Eligibility:

• You must have IR NMIBC as per medical guidelines and have undergone specific surgery.
• You cannot participate if you have a more serious form of bladder cancer or if it has spread to muscles or other parts of the body.

Key Points:

• The study involves comparing a medication with no treatment.
• Participants need to have had tumor removal surgery recently.
• The study is randomized, meaning treatment is assigned by chance.